TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01949363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
Study: NCT06293612

Intervention type: OTHER
Intervention: No intervention was administrated to the two cohorts.

Intervention type: OTHER
Intervention: No intervention was administrated to the two cohorts.
Study: NCT01902290

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Brodalumab administered subcutaneously
Study: NCT00246428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Experimental manipulations will be evaluated 6, 9, and 12 months
Study: NCT03042715

Intervention type: BEHAVIORAL
Intervention: Qualitative Interviews
Description: phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
Study: NCT02161211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De-coupling
Description: Six sessions of CBT for anxiety-alcohol de-coupling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Reduction
Description: Six sessions of CBT for anxiety reduction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined
Description: Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
Study: NCT02865382

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: white light was used for colonoscopy withdrawal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OE mode was used for colonoscopy withdrawal
Study: NCT02948803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone based intervention with Active Coach app
Study: NCT01312935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMX-60056
Description: investigational drug
Study: NCT02776800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allevyn Life

Intervention type: DEVICE
Group type: OTHER
Intervention: Foam dressing with an integrated adhesive border
Description: Foam dressing normally used by the home health agency
Study: NCT03926221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)
Description: PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
Study: NCT02497859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Egg Breakfast (EB)
Description: The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cereal Breakfast (CB)
Description: The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Counseling
Description: Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Diet
Description: Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Diet
Description: Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
Study: NCT00953758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913
Description: Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
Study: NCT01698346

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis vaccine
Description: Vaccination during pregnancy with a pertussis containing vaccine
Study: NCT03223753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational handouts about to physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational handouts about to physical activity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Intervention
Description: Access limited version of device app/website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Access full version of interactive reward-based device app/website

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear physical activity tracking device
Study: NCT00685126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl Inhalation Solution
Description: Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
Study: NCT03223753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear physical activity tracking device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00685126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HCl Inhalation Solution
Description: Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HCl Inhalation Solution
Description: Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
Study: NCT02765074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous tocilizumab
Description: 162 mg subcutaneous, once a week during 12 months
Study: NCT01329393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefits Management
Description: Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Illness Management and Recovery
Description: Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
Study: NCT02733770

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: Doppler ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: Doppler ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic mini gastric bypass
Description: Doppler ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic mini gastric bypass
Description: Doppler ultrasound.
Study: NCT03223753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04336995

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: contrast echocardiography
Description: giving echocardiographic contrast and taking echocardiographic images before and after exercise
Study: NCT01188083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose Drink
Description: Fructose Based beverage 8 oz

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose Drink
Description: Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
Study: NCT01662583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written reminder

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written reminder

Intervention type: OTHER
Group type: OTHER
Intervention: Written reminder
Study: NCT02789865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem, Levofloxacin and Metronidazole
Description: The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde appendicitis therapy (ERAT)
Description: The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
Study: NCT02171754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBW 2992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT02789865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: The patients will receive laparoscopic appendectomy according to standard routines.
Study: NCT01052584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine- P. vivax
Description: Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine: P. vivax
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine: P. falciparum
Description: administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
Study: NCT01839864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
Description: Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
Study: NCT02926950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet. Route of administration: oral.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet. Route of administration: oral.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet. Route of administration: oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet. Route of administration: oral.
Study: NCT01387893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Digital Repetitive Infrapubic Pressure maneuver
Description: The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
Study: NCT00993031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: LPV 200mg/r 50mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Zidovudine 300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: Zidovudine 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Lamivudine 150 mg
Study: NCT01568593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T2750
Description: 1 drop in each eye 3 to 6 times daily during 84 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed
Description: 1 drop in each eye 3 to 6 times daily during 84 days
Study: NCT04534660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMI-01
Description: SMI-01 is a device consisting of silk particles in a hydrogel carrier.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMI-01
Description: SMI-01 is a device consisting of silk particles in a hydrogel carrier.
Study: NCT00868283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: 30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline Solution
Description: 30 ml will be given once daily by intravenous infusion for 10 consecutive days.
Study: NCT01622881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
Study: NCT02971670

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rTSST-1 Variant Candidate Vaccine
Description: Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTSST-1 Variant Candidate Vaccine
Description: Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTSST-1 Variant Candidate Vaccine
Description: Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rTSST-1 Variant Candidate Vaccine
Description: Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
Study: NCT02895061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: Alfacalcidol 1 microgram/capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Description: Alfacalcidol 1 microgram/capsule
Study: NCT01665118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trusculpt (Radio Frequency) Device
Study: NCT03250403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: peri-neural injection of platelet rich plasma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional medical treatment
Description: traditional medical treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional medical treatment
Description: traditional medical treatment
Study: NCT00884104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Oral
Study: NCT02224378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peep induced CVP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: passive leg raising(PLR)
Study: NCT02772861

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement - One dose
Description: 20gr

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement - One dose
Description: 20gr

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement - One dose
Description: 20gr

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid Supplement - One dose
Description: 20gr

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-Methylhistidine
Description: 120mgr
Study: NCT00237003

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational interviewing
Description: Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
Study: NCT04697498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral bi-level Erector spine plane block
Description: After intubation of the trachea and rotation on the abdomen before the skin incision will be performed bilateral bi-level Erector spine plane block. Before surgery, the level of screw placement will be discussed with the surgeon, and the blockade will be performed at two levels of the spine bilaterally as close as possible to the screw placement site. For blockade a solution for prolonged blockade of peripheral nerve plexuses with bupivacaine 0.375%, dexamethasone 0.02% and epinephrine 0.00018% will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: The control group - will include patients who will undergo surgery under general anaesthesia
Study: NCT02844114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum spore
Description: G 300mg, 5 tablets by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic tramadol 1500mg tablet
Study: NCT03223233

Intervention type: OTHER
Intervention: procalcitonin level
Description: serum procalcitonin level will be measured in both groups.
Study: NCT02844114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: iv.30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: iv.30 minutes
Study: NCT04477486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Capsule; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study: NCT02303548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Administer Sodium bicarbonate 50 mEq IV over 2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT04119349

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra counseling
Description: Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
Study: NCT01861210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples Voluntary HIV Counseling and Testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Counseling and Testing
Study: NCT04842162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: indocyanine green (INFRACYANINE© 25mg/10mL).